{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:50:57Z","timestamp":1783032657177,"version":"3.54.6"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012331","name":"LEO Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004196","name":"Odense University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100028926","name":"Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100028926","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Topical drugs containing corticosteroids are the recommended first-line treatment for mild-to-moderate psoriasis, although the optimal dosage has not been established.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate the effect of topical drug application quantity and treatment duration on psoriasis treatment outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a post hoc analysis of two randomized controlled trials investigating 214 patients with psoriasis treated using topical drugs containing corticosteroids and\/or calcipotriol for up to 48 weeks. We measured the quantity of topical drugs used during the study period and calculated the mean quantity of applied drugs per 1% affected body surface area (BSA) divided by the number of days in the study period. Improvements in psoriasis were measured using the Lattice System Physician\u2019s Global Assessment (LS-PGA) (where affected BSA is categorized into seven levels) from baseline to final visit. Descriptive results were reported as counts with proportions and as means with normality-based confidence intervals (CIs). Associations were analysed using linear regressions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Most study participants had a duration of psoriasis &amp;gt; 20\u2005years, moderate psoriasis and no history of receiving systemic psoriasis treatment. They applied a mean of 1.0\u2005g per 1% affected BSA daily (95% CI 0.9\u20131.2). Daily use of topical drugs for 4 weeks reduced the severity of psoriasis, while extended daily use for up to 48 weeks provided further reductions in disease severity (coefficients \u20130.30, 95% CI \u20130.51 to \u20130.09 and \u20130.73, 95% CI \u20131.09 to \u20130.38, respectively; P = 0.03). Increasing the quantity of topical drugs applied reduced psoriasis severity in a linear manner. Each increase of 1\u2005g of topical drugs applied per 1% affected BSA daily reduced LS-PGA by 0.43 (95% CI 0.24\u20130.61). Patients who had never received systemic drugs experienced a greater reduction in psoriasis when applying the same mean quantity of topical drugs (coefficient \u20130.7, 95% CI \u20131.1 to \u20130.4) compared with patients with a history of systemic treatment (\u20130.3, 95% CI \u20130.5 to \u20130.1; P = 0.03).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The application of a mean quantity of at least 1.0\u2005g of topical drugs per 1% affected BSA daily is safe and effective and can be used daily until clearance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ced\/llaf349","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T11:50:39Z","timestamp":1753876239000},"page":"92-97","source":"Crossref","is-referenced-by-count":1,"title":["Increasing the quantity of topical corticosteroids applied reduces the severity of psoriasis: results from two randomized controlled trials"],"prefix":"10.1093","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4317-0873","authenticated-orcid":false,"given":"Mathias Tiedemann","family":"Svendsen","sequence":"first","affiliation":[{"name":"Department of Clinical Research, University of Southern Denmark , Odense ,","place":["Denmark"]},{"name":"Department of Dermatology and Allergy Centre, Odense University Hospital , Odense ,","place":["Denmark"]},{"name":"Open Patient data Exploratory Network (OPEN), Odense University Hospital , Odense ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0858-4269","authenticated-orcid":false,"given":"S\u00f6ren","family":"M\u00f6ller","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, University of Southern Denmark , Odense ,","place":["Denmark"]},{"name":"Open Patient data Exploratory Network (OPEN), Odense University Hospital , Odense ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R","family":"Feldman","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, University of Southern Denmark , Odense ,","place":["Denmark"]},{"name":"Department of Dermatology and Allergy Centre, Odense University Hospital , Odense ,","place":["Denmark"]},{"name":"Department of Dermatology, Wake Forest University School of Medicine , Winston-Salem, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus Ejner","family":"Andersen","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, University of Southern Denmark , Odense ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"2025122312171830400_llaf349-B1","doi-asserted-by":"crossref","first-page":"103287","DOI":"10.1016\/j.annder.2024.103287","article-title":"Treatment of moderate-to-severe psoriasis in adults: an expert consensus statement using a Delphi method to produce a decision-making algorithm","volume":"151","author":"Poizeau","year":"2024","journal-title":"Ann Dermatol Venereol"},{"key":"2025122312171830400_llaf349-B2","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/bjd.21047","article-title":"Systematic review and critical appraisal of psoriasis clinical practice guidelines: a Global Guidelines in Dermatology Mapping Project (GUIDEMAP)","volume":"187","author":"Yen","year":"2022","journal-title":"Br J Dermatol"},{"key":"2025122312171830400_llaf349-B3","doi-asserted-by":"crossref","first-page":"e3061","DOI":"10.1136\/bmj.e3061","article-title":"Defining the fingertip unit","volume":"344","author":"Finlay","year":"2012","journal-title":"BMJ"},{"key":"2025122312171830400_llaf349-B4","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1365-2230.1991.tb01232.x","article-title":"The finger-tip unit \u2013 a new practical measure","volume":"16","author":"Long","year":"1991","journal-title":"Clin Exp Dermatol"},{"key":"2025122312171830400_llaf349-B5","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/bjd.16667","article-title":"A smartphone application supporting patients with psoriasis improves adherence to topical treatment: a randomized controlled trial","volume":"179","author":"Svendsen","year":"2018","journal-title":"Br J Dermatol"},{"key":"2025122312171830400_llaf349-B6","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1111\/ced.15370","article-title":"Regular support provided by dermatological nurses improves outcomes in patients with psoriasis treated with topical drugs: a randomized controlled trial","volume":"47","author":"Svendsen","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"2025122312171830400_llaf349-B7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jaad.2019.08.026","article-title":"Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council","volume":"82","author":"Strober","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025122312171830400_llaf349-B8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(89)90204-3","article-title":"\u201cFingertip unit\u201d in dermatology","volume":"2","author":"Finlay","year":"1989","journal-title":"Lancet"},{"key":"2025122312171830400_llaf349-B9","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000246851","article-title":"Long-term use of topical calcipotriol in chronic plaque psoriasis","volume":"189","author":"Ramsay","year":"1994","journal-title":"Dermatology"},{"key":"2025122312171830400_llaf349-B10","first-page":"205","article-title":"Calcitriol ointment 3 microg\/g is safe and effective over 52 weeks for the treatment of mild to moderate plaque psoriasis","volume":"83","author":"Lebwohl","year":"2009","journal-title":"Cutis"},{"key":"2025122312171830400_llaf349-B11","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1046\/j.1365-2133.1996.d01-1009.x","article-title":"A long-term multicentre assessment of the safety and tolerability of calcitriol ointment in the treatment of chronic plaque psoriasis","volume":"135","author":"Langner","year":"1996","journal-title":"Br J Dermatol"},{"key":"2025122312171830400_llaf349-B12","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1046\/j.1525-1470.1999.00084.x","article-title":"A pilot study to assess the safety and efficacy of topical calcipotriol treatment in childhood psoriasis","volume":"16","author":"Park","year":"1999","journal-title":"Pediatr Dermatol"},{"key":"2025122312171830400_llaf349-B13","first-page":"199","article-title":"Long-term treatment of psoriasis with calcipotriol scalp solution and cream","volume":"10","author":"Barnes","year":"2000","journal-title":"Eur J Dermatol"},{"key":"2025122312171830400_llaf349-B14","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1046\/j.1365-2133.1998.02411.x","article-title":"The effect of long-term treatment with tacalcitol on the psoriatic epidermis. A flow cytometric analysis","volume":"139","author":"Mommers","year":"1998","journal-title":"Br J Dermatol"},{"key":"2025122312171830400_llaf349-B15","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1046\/j.1365-2133.2002.04567.x","article-title":"Long-term efficacy and safety of tacalcitol ointment in patients with chronic plaque psoriasis","volume":"146","author":"van de Kerkhof","year":"2002","journal-title":"Br J Dermatol"},{"key":"2025122312171830400_llaf349-B16","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000063376","article-title":"Tacalcitol ointment for long-term control of chronic plaque psoriasis in dermatological practice","volume":"204","author":"Lambert","year":"2002","journal-title":"Dermatology"},{"key":"2025122312171830400_llaf349-B17","first-page":"463","article-title":"Long-term safety and efficacy of high-concentration (20 microg\/g) tacalcitol ointment in psoriasis vulgaris","volume":"12","author":"Miyachi","year":"2002","journal-title":"Eur J Dermatol"},{"key":"2025122312171830400_llaf349-B18","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/bjd.12895","article-title":"Calcipotriol\/betamethasone dipropionate ointment in mild-to-moderate paediatric psoriasis: long-term daily clinical practice data in a prospective cohort","volume":"171","author":"van Geel","year":"2014","journal-title":"Br J Dermatol"},{"key":"2025122312171830400_llaf349-B19","first-page":"2018","article-title":"Proactive vs. reactive psoriasis therapy: a long-term evaluation with dermoscopic and confocal microscopy assessment","volume":"26","author":"Cacciapuoti","year":"2022","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2025122312171830400_llaf349-B20","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/jdv.18053","article-title":"Impact of fixed-dose combination Cal\/BD foam on the work productivity of patients with psoriasis: results from the 52-week randomized, double-blind, PSO-LONG trial","volume":"36","author":"Guenther","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025122312171830400_llaf349-B21","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1111\/jdv.13230","article-title":"Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52-week PRO-long study","volume":"29","author":"Lambert","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025122312171830400_llaf349-B22","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/jdv.13865","article-title":"Optimal maintenance treatment with calcipotriol\/betamethasone dipropionate gel in Korean patients with psoriasis vulgaris: a multicentre randomized, controlled clinical trial","volume":"31","author":"Lee","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025122312171830400_llaf349-B23","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/jdv.12789","article-title":"Treatment of paediatric scalp psoriasis with calcipotriene\/betamethasone dipropionate scalp formulation: effectiveness, safety and influence on children\u2019s quality of life in daily practice","volume":"29","author":"Oostveen","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025122312171830400_llaf349-B24","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3109\/09546630903493311","article-title":"Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of moderate scalp psoriasis","volume":"21","author":"Poulin","year":"2010","journal-title":"J Dermatolog Treat"},{"key":"2025122312171830400_llaf349-B25","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s00403-024-03066-1","article-title":"Analysis of factors influencing target PASI responses and side effects of methotrexate monotherapy in plaque psoriasis: a multicenter study of 1521 patients","volume":"316","author":"Erduran","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"2025122312171830400_llaf349-B26","doi-asserted-by":"crossref","first-page":"2430687","DOI":"10.1080\/09546634.2024.2430687","article-title":"Assessing secondary adherence to topical treatments: scoping review revealing lack of standardized approach in clinical research","volume":"35","author":"Balding","year":"2024","journal-title":"J\u00a0Dermatolog Treat"},{"key":"2025122312171830400_llaf349-B27","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1007\/s11606-020-05905-z","article-title":"Using electronic monitoring devices to assess medication adherence: a research methods framework","volume":"35","author":"McGrady","year":"2020","journal-title":"J Gen Intern Med"},{"key":"2025122312171830400_llaf349-B28","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1001\/archderm.1992.01680180125022","article-title":"The rule of hand: 4 hand areas = 2 FTU = 1\u2005g","volume":"128","author":"Long","year":"1992","journal-title":"Arch Dermatol"},{"key":"2025122312171830400_llaf349-B29","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/0305-4179(95)00118-2","article-title":"How big is a hand?","volume":"22","author":"Rossiter","year":"1996","journal-title":"Burns"},{"key":"2025122312171830400_llaf349-B30","doi-asserted-by":"crossref","first-page":"5651","DOI":"10.1136\/bmj.h5651","article-title":"Three simple rules to ensure reasonably credible subgroup analyses","volume":"351","author":"Burke","year":"2015","journal-title":"BMJ"},{"key":"2025122312171830400_llaf349-B31","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1080\/09546634.2019.1675855","article-title":"Psoriasis patient preferences for topical drugs: a systematic review","volume":"32","author":"Svendsen","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"2025122312171830400_llaf349-B32","doi-asserted-by":"crossref","first-page":"2298880","DOI":"10.1080\/09546634.2023.2298880","article-title":"Evaluation of psoriasis patients with long-term topical corticosteroids for their risk of developing adrenal insufficiency, Cushing\u2019s syndrome and osteoporosis","volume":"35","author":"Erdem","year":"2024","journal-title":"J Dermatolog Treat"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf349\/63895683\/llaf349.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/1\/92\/63895683\/llaf349.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/1\/92\/63895683\/llaf349.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T17:17:26Z","timestamp":1766510246000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/1\/92\/8219489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,7,30]]},"published-print":{"date-parts":[[2025,12,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf349","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,7,30]]}}}